Earnings Insights · Edwards Lifesciences (EW) · Q3 FY2026

Edwards Lifesciences (EW) Q3 FY2026: Edwards Lifesciences Q3 2026 Earnings: TAVR and TMTT Strength Drive Higher Full-Year Outlook

By AlgovestIQ ResearchPublished

Share

Read Edwards Lifesciences’s results announcement (Form 8-K, filed Nov 4, 2026)

Key earnings findings

Edwards Lifesciences (EW) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Edwards Lifesciences reported Q3 FY2026 revenue of $1.72B against the $1.68B analyst estimate, a 2.1% beat, and EPS of $0.80 against the $0.74 analyst estimate, a 7.5% beat.
  2. EW closed at $100.82 on Nov 5, 2026, up 1.5% from $99.37 on Nov 4, 2026, the last close before the results were released.
  3. Edwards Lifesciences reported third-quarter sales of $1.72B, up 10.5% reported and 11.2% on a constant-currency basis, while adjusted EPS rose 19% to $0.80.

Sources: Edwards Lifesciences results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Edwards Lifesciences beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$1.72B
$1.68B
+2.1%
EPS
$0.80
$0.74
+7.5%
  • EPS has beaten the estimate in 3 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from 0.9% to 3.7%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Edwards Lifesciences reported third-quarter sales of $1.72B, up 10.5% reported and 11.2% on a constant-currency basis, while adjusted EPS rose 19% to $0.80. Growth was led by TMTT therapies, where sales increased 45.6% in constant currency, while TAVR grew 8.8% as procedure volumes improved and pricing remained stable.

The company raised its 2026 sales, TAVR, TMTT, and adjusted EPS outlook. The central investment issue is increasingly less about near-term share gains in TAVR and more about whether clinical evidence, expanded coverage, and earlier treatment pathways can lift procedure volumes over several years while TMTT becomes a larger contributor to growth.

Earnings Snapshot

As Reported on the Call

MetricReportedChange
Total sales$1.72B+10.5% reported; +11.2% constant currency
TAVR sales$1.24B+8.0% reported; +8.8% constant currency
TMTT sales$207M adjusted+44.0% reported; +45.6% constant currency
Surgical sales$264M+2.5% reported; +2.8% constant currency
U.S. sales$1.01B+11.0%
Sales outside the U.S.$707.9M+9.7% reported; +11.5% constant currency
GAAP diluted EPS from continuing operations$0.53+6%
Adjusted diluted EPS$0.80+19%
GAAP gross margin78.5%Up from 77.8%
Adjusted gross margin78.7%Up from 77.9%
GAAP operating margin17.4%Down from 19.8%
Adjusted operating margin30.3%Up from 27.5%
Cash and cash equivalents$3.1BAs of Sept. 30, 2026
Total debt$600MAs of Sept. 30, 2026

The Bigger Story

The quarter reinforced Edwards’ transition toward a broader structural-heart growth model. TAVR remains the dominant business, accounting for roughly three-quarters of quarterly sales, but TMTT is becoming a meaningful incremental growth engine as PASCAL, EVOQUE, and SAPIEN M3 gain adoption.

TAVR growth also appears to be shifting in composition. Management said Edwards had benefited from modest share gains over recent quarters, including the annualization of Boston Scientific’s exit from the European TAVR market. Going forward, however, management expects growth to be driven primarily by procedure volumes rather than further share gains.

That distinction matters. Share gains can provide a temporary tailwind, while broader procedure growth would support a more durable expansion of the TAVR market. Management cited encouraging procedure trends exiting the third quarter, supported by clinical evidence favoring earlier intervention and an updated U.S. Medicare coverage policy.

The long-term opportunity is not yet a near-term revenue event. Edwards’ PROGRESS trial data in moderate aortic stenosis and the expansion of coverage for asymptomatic patients could enlarge the treated population over time, but management stressed that adoption, site implementation, physician education, and potential new indications will develop gradually.

Revenue and Operating Performance

Total third-quarter sales rose $162.4M year over year to $1.72B. Currency reduced reported growth by approximately $9.8M, or 70 basis points, leaving underlying growth at 11.2%.

TAVR sales increased 8.0% reported to $1.24B and 8.8% in constant currency. Management attributed the result principally to stronger procedure volumes, a heightened focus on TAVR among physicians, and clinical evidence supporting proactive management of aortic stenosis. Global average selling prices were stable.

U.S. TAVR procedure growth continued to benefit from adoption of the SAPIEN 3 Ultra RESILIA platform. Management said its U.S. competitive position was stable sequentially and modestly higher than a year earlier. In Europe, Edwards also reported modest year-over-year competitive gains, while Japan benefited from continued adoption of SAPIEN 3 Ultra RESILIA and dedicated reimbursement for the product.

TMTT was the fastest-growing business. Adjusted TMTT sales reached $207M, up 45.6% in constant currency. Product-group revenue was $209.5M including $2.9M of Implantable Heart Failure Management revenue. Management said mitral and tricuspid procedure volumes grew at a double-digit rate globally, with the U.S. becoming a more meaningful contributor as therapies scale.

The TMTT portfolio is broadening commercially. Edwards received U.S. approval for PASCAL Ace with Capture Clarity for degenerative mitral transcatheter edge-to-edge repair during the quarter, followed by October approval of PASCAL Precision for tricuspid regurgitation. The company also cited continued demand for SAPIEN M3 among patients not suited for mitral TEER and ongoing growth from EVOQUE for tricuspid replacement.

Surgical sales rose 2.5% reported, or 2.8% in constant currency, to $264M. Growth reflected adoption of RESILIA tissue technologies, though the business grew substantially more slowly than the company’s transcatheter franchises. Surgical sales included $1.5M of revenue from a transitional service agreement related to the 2025 sale of a non-product business.

Profitability and Margins

Adjusted profitability improved materially despite continued investment in product launches, clinical programs, and patient access. Adjusted operating margin expanded 280 basis points year over year to 30.3%, and adjusted EPS increased to $0.80 from $0.67.

The adjusted EPS result benefited from higher-than-expected sales and the planned timing of R&D and SG&A investments during the year. Management expects spending to rise sequentially in the fourth quarter, implying an adjusted operating margin in the mid-20% range.

Gross margin improved as manufacturing efficiencies and foreign exchange more than offset the expected dilution from scaling newer therapies. Adjusted gross margin was 78.7%, up 80 basis points from a year earlier. Foreign exchange provided a 50-basis-point benefit to third-quarter gross margin versus the prior year.

GAAP results were less favorable. GAAP operating margin fell to 17.4% from 19.8%, and GAAP EPS was $0.53. The principal difference was a $220.2M impairment charge tied to certain acquired in-process R&D and fixed assets. The quarter also included an $8.7M acquisition-contract termination cost and a $2.0M restructuring charge, partly offset by a $12.7M net insurance recovery related to litigation.

R&D spending was essentially flat in dollars at $281M, but declined to 16.4% of sales from 18.1%, reflecting revenue growth. SG&A rose to $561M but improved as a percentage of sales to 32.7% from 33.1%.

Demand, Customers and Pricing

TAVR demand appears to be improving, although management did not suggest a sharp near-term inflection. The company said procedure trends were positive exiting the quarter and that market growth, rather than share gains, should be the primary driver in the fourth quarter and beyond.

The updated Medicare national coverage determination is strategically important because it expands coverage to asymptomatic patients, provides greater flexibility in patient evaluation and treatment, updates hospital volume requirements, and creates a potential path for coverage of future approved indications. Management expects the impact to build progressively rather than appear as a single-year surge.

Clinical evidence is central to Edwards’ market-development strategy. The PROGRESS trial examined TAVR in moderate aortic stenosis patients with at-risk features, while the EARLY TAVR program supports earlier treatment in asymptomatic severe disease. Management views moderate aortic stenosis as a sizable underserved population, but has not provided a regulatory submission or approval timeline for that indication.

In TMTT, demand is being supported by a broader treatment portfolio rather than a single product. PASCAL offers repair options in mitral and tricuspid disease, while EVOQUE and SAPIEN M3 address replacement opportunities. The challenge is execution: these therapies remain earlier in their adoption curves and require physician training, procedural expertise, and continued clinical evidence to support wider use.

What Is Edwards Lifesciences’ Guidance for Q4 and Full-Year 2026?

For the fourth quarter, Edwards projects total sales of $1.67B to $1.75B and adjusted EPS of $0.61 to $0.69.

For full-year 2026, management increased its total company sales-growth outlook to approximately 11.5% on a constant-currency basis, from 10% to 11% previously. It also raised TAVR growth guidance to 9% to 9.5%, from 8% to 9%.

Management raised TMTT sales guidance to $780M to $790M, from $760M to $780M, while reaffirming mid-single-digit sales growth guidance for Surgical. Adjusted EPS guidance increased to $2.97 to $3.05 from $2.95 to $3.05.

Edwards continues to expect adjusted gross margin at the lower end of its 78% to 79% range, reflecting the effect of currency hedging. Management expects full-year adjusted operating margin at the high end of its original 28% to 29% range, representing approximately 150 basis points of constant-currency expansion.

Management expects R&D expense to be about 16.5% of sales for the full year and its adjusted tax rate to be at the high end of the prior 16% to 19% range. If exchange rates remain near current levels, management expects foreign exchange to reduce fourth-quarter sales by approximately $15M year over year.

Balance Sheet, Cash Flow and Capital

Edwards ended the quarter with approximately $3.1B of cash and cash equivalents against approximately $600M of total debt, preserving substantial balance-sheet flexibility.

The company repurchased about $700M of shares through the first nine months of 2026 and had approximately $1.3B remaining under its authorization. Average diluted shares outstanding were 578 million during the quarter, compared with 586 million a year earlier.

The repurchase activity supports EPS growth, but the larger earnings driver remains operating leverage from revenue growth. Management continues to target 50 to 100 basis points of underlying operating-margin expansion beyond 2026 while investing in structural-heart innovation.

What Investors Should Watch

1. TAVR Procedure Growth

Management expects future TAVR growth to depend more on market expansion than share gains. Investors should watch whether procedure-volume momentum continues through the fourth quarter and into 2027, particularly as the updated Medicare coverage policy is implemented.

2. Adoption of Earlier-Intervention Pathways

The updated coverage policy and clinical evidence in asymptomatic severe and moderate aortic stenosis could expand the eligible patient pool. The key variable is the pace at which physicians, heart teams, and hospitals change referral and treatment practices.

3. TMTT Revenue Scale and Execution

TMTT is growing rapidly and management now expects $780M to $790M in 2026 sales. Sustaining that trajectory will depend on successful rollout of PASCAL’s new mitral and tricuspid indications, EVOQUE adoption, and continued demand for SAPIEN M3.

4. Margin Performance in the Fourth Quarter

Third-quarter adjusted margins benefited from sales outperformance and planned expense phasing. The expected mid-20% fourth-quarter operating margin will show whether Edwards can preserve its broader operating-leverage trajectory while increasing commercial and R&D spending.

5. Impairment and Portfolio Investment Discipline

The $220.2M impairment charge reduced GAAP earnings and highlights the risk inherent in acquired R&D assets and early-stage structural-heart investments. Investors should monitor whether future portfolio expansion produces commercial growth without recurring impairment or acquisition-related charges.

AlgovestIQ Takeaway

Edwards delivered a stronger quarter on both revenue and adjusted earnings, and the raised outlook reflects real operating momentum rather than a one-time accounting benefit. TAVR growth accelerated, TMTT continued to scale rapidly, and gross-margin expansion showed that new-therapy investments have not yet disrupted the company’s underlying profitability model.

The most important positive change is the emerging case for TAVR market expansion. Edwards has clinical evidence supporting earlier aortic-stenosis intervention and an updated U.S. coverage framework that could improve access. Management’s commentary that recent TAVR growth is increasingly procedural rather than share-driven is constructive if it proves durable.

Still, the opportunity should be viewed as gradual. The updated coverage policy, asymptomatic patient access, and potential moderate-aortic-stenosis indication require implementation, physician education, and new referral behavior. Management has indicated these factors should build over multiple years rather than create an immediate step-change in revenue.

TMTT provides a second leg of growth, but it remains an execution-intensive business. The portfolio is broad and gaining regulatory clearances, yet adoption depends on training, procedural outcomes, and the ability to establish repair and replacement therapies across complex patient populations.

The central question is whether Edwards can convert its clinical and regulatory milestones into sustained procedure growth while maintaining operating leverage. Continued high-single-digit TAVR growth driven by volumes, durable TMTT expansion, and margins that hold near management’s longer-term targets would strengthen that case. Slower procedure adoption, a return to share pressure, or greater-than-expected investment needs would weaken it.

How did EW stock react?

EW closed at $100.82 on Nov 5, 2026, up 1.5% from $99.37 on Nov 4, 2026, the last close before the results were released.

SessionCloseChange
Nov 4, 2026 (before release)$99.37—
Nov 5, 2026$100.82+1.5%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Edwards Lifesciences Q3 FY2026 earnings call transcript, as of Nov 4, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Edwards Lifesciences Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 4, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 4, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against Edwards Lifesciences' earnings release and call transcript before publication. Not investment advice.